GRI Bio discusses positive Phase 2a IPF data for GRI-0621
GRI Bio discussed positive Phase 2a idiopathic pulmonary fibrosis data for GRI-0621, highlighting biomarker results indicating improvements in fibrosis and lung repair.
GRI Bio, Inc. discussed positive Phase 2a data in idiopathic pulmonary fibrosis during a virtual investor segment, highlighting key biomarker results. The reported data includes biomarker results indicating significant improvements in key factors related to fibrosis and lung repair. GRI-0621 is being evaluated in a Phase 2a study for idiopathic pulmonary fibrosis.
GRI Bio, Inc. is a Nasdaq-listed clinical-stage biotechnology company focused on developing therapies to treat inflammatory, fibrotic and autoimmune disorders. The lead program, GRI-0621, targets type-1 natural killer T cells, or type-1 NKT cells, and is being evaluated in fibrotic lung disease indications. Mechanistically, GRI’s approach focuses on modulating innate-like T cell activity to reduce pro-fibrotic signaling and inflammation.
GRI-0621 is an oral inhibitor that selectively targets type-1 NKT cell pathways implicated in fibrotic and inflammatory processes. The company said its lead program aims to inhibit harmful immune cell activity and is intended as a novel oral treatment for IPF. The company also has a growing pipeline of compounds aimed at various diseases, including systemic lupus erythematosus.
The company is headquartered in La Jolla, California. As a clinical-stage firm, revenue is limited and the company primarily funds operations through equity financing and, at times, debt or collaborative agreements.